Document Detail

Pharmacokinetics of sertraline across pregnancy and postpartum.
MedLine Citation:
PMID:  19011433     Owner:  NLM     Status:  MEDLINE    
Insufficient data inform dosing of antidepressants and clinical monitoring for major depressive disorder (MDD) during the perinatal period. The objectives were to assess the pharmacokinetics of sertraline (SER) across pregnancy and postpartum. Participants treated with SER for MDD underwent serial sampling to measure steady-state concentrations of SER and norsertraline during the second and third trimesters and postpartum (total of 3 assessments). Blood was drawn before observed SER administration and 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours after administration. A sensitive high-performance liquid chromatography/mass spectrometric method for simultaneous determination of serum concentrations of SER and norsertraline was developed and validated. For each sampling period for SER, area under the serum concentration versus time curve, maximal serum concentration (Cmax), and the time at which Cmax occurred (Tmax) were determined. Of 11 women initially enrolled, 6 completed second- and third-trimester assessments, and 3 completed all 3 assessments (including the postpartum assessment). Mean changes on all pharmacokinetic parameters were nonsignificant between assessments, although there was a marked heterogeneity among individuals. Results were not significantly altered by incorporation of body weights into the analyses. The range of pharmacokinetic changes between individuals was broad, indicating heterogeneity regarding the impact of pregnancy on SER metabolism. Overall, lowest observed SER area under the curve and Cmax occurred in the third trimester (observed in 5 of 6 participants). Despite nonsignificant mean pharmacokinetic changes, the range of pharmacokinetic changes across pregnancy warrants careful monitoring of depressive symptoms in women with MDD in late pregnancy and further study.
Marlene P Freeman; Paul E Nolan; Melinda F Davis; Marietta Anthony; Karen Fried; Martha Fankhauser; Raymond L Woosley; Francisco Moreno
Related Documents :
12132613 - Changes in gustatory sense during pregnancy.
19499513 - Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders ...
238853 - Beta-adrenergic blockade and atrio--ventricular conduction impairment.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of clinical psychopharmacology     Volume:  28     ISSN:  1533-712X     ISO Abbreviation:  J Clin Psychopharmacol     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-11-17     Completed Date:  2009-02-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8109496     Medline TA:  J Clin Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  646-53     Citation Subset:  IM    
Department of Psychiatry, Women's Mental Health Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
1-Naphthylamine / analogs & derivatives,  pharmacokinetics
Body Weight
Depressive Disorder, Major / drug therapy*,  metabolism
Longitudinal Studies
Postpartum Period / metabolism*
Pregnancy Complications / drug therapy*,  metabolism
Pregnancy Trimester, Second / metabolism*
Pregnancy Trimester, Third / metabolism*
Serotonin Uptake Inhibitors / blood,  pharmacokinetics*,  therapeutic use
Sertraline / blood,  pharmacokinetics*,  therapeutic use
Young Adult
Grant Support
Reg. No./Substance:
0/Serotonin Uptake Inhibitors; 0/norsertraline; 134-32-7/1-Naphthylamine; 79617-96-2/Sertraline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A double-masked, placebo-controlled study of fluoxetine for hypochondriasis.
Next Document:  Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a...